{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:28Z","timestamp":1793289628549,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.jhep.2010.03.013","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T08:58:51Z","timestamp":1274518731000},"page":"273-282","source":"Crossref","is-referenced-by-count":122,"title":["Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"53","author":[{"given":"Puneeta","family":"Tandon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Berzigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Garcia-Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.03.013_bib1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"HVPG reduction and prevention of variceal bleeding in cirrhosis. A systematic review","volume":"131","author":"D\u2019Amico","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1572-0241.2006.00453.x","article-title":"Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis","volume":"101","author":"Turnes","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(95)91740-3","article-title":"Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis","volume":"346","author":"Feu","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2010.03.013_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2007.01.017","article-title":"AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers","volume":"46","author":"Debernardi-Venon","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.TP.0000128913.09774.CE","article-title":"Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation","volume":"78","author":"Rimola","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.03.013_bib8","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.3748\/wjg.v12.i42.6786","article-title":"Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C","volume":"12","author":"Yoshiji","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hep.1840190506","article-title":"Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis","volume":"19","author":"Garcia-Pagan","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2010.03.013_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.510290203","article-title":"Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis","volume":"29","author":"Schneider","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2003.07497.x","article-title":"Portal pressure response to losartan compared with propranolol in patients with cirrhosis","volume":"98","author":"De","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/gast.2001.26288","article-title":"Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis","volume":"121","author":"Gonzalez-Abraldes","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jhep.2010.03.013_bib16","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.288.19.2406-JLT1120-4-1","article-title":"Allocation concealment in clinical trials","volume":"288","author":"Schulz","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2010.03.013_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.1995.03530180050029","article-title":"Subverting randomization in controlled trials","volume":"274","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2010.03.013_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1023\/A:1013790610327","article-title":"Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension","volume":"47","author":"Debernardi-Venon","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2010.03.013_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2362.1981.tb01844.x","article-title":"Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin\u2013angiotensin\u2013aldosterone system in cirrhosis with ascites","volume":"11","author":"Arroyo","year":"1981","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2010.03.013_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s005350200020","article-title":"One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites","volume":"37","author":"Yang","year":"2002","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0016-5085(85)80088-3","article-title":"Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites","volume":"88","author":"Pariente","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF02285088","article-title":"Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis","volume":"43","author":"Ibarra","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2010.03.013_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1572-0241.2005.41168.x","article-title":"A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension","volume":"100","author":"Sookoian","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1440-1746.1995.tb01090.x","article-title":"Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis","volume":"10","author":"Chiang","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1572-0241.2004.04051.x","article-title":"Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis","volume":"99","author":"Tripathi","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32679","article-title":"Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C","volume":"36","author":"Terui","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-9343(84)90887-8","article-title":"Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis","volume":"76","author":"Eriksson","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2010.03.013_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0168-8278(87)80542-1","article-title":"Effects of captopril on renal function in patients with cirrhosis and ascites","volume":"4","author":"Daskalopoulos","year":"1987","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib29","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.3748\/wjg.v11.i48.7560","article-title":"Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study","volume":"11","author":"Sookoian","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.510230517","article-title":"The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites","volume":"23","author":"Nevens","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib31","first-page":"795","article-title":"Effects of angiotensin-converting enzyme inhibitors and sclerotherapy on portal hemodynamics in patients with portal hypertension","volume":"47","author":"Nasr","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib32","first-page":"783","article-title":"Effects of losartan, somatostatin and losartan plus somatostatin on portal hemodynamics and renal functions in cirrhosis","volume":"49","author":"Hulagu","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/gut.46.1.114","article-title":"Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis","volume":"46","author":"Girgrah","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2010.03.013_bib34","first-page":"171","article-title":"Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy","volume":"53","author":"Wagatsuma","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib35","first-page":"887","article-title":"Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis","volume":"43","author":"Koda","year":"1996","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib36","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3748\/wjg.15.2512","article-title":"Relationship between angiotensin-(1\u20137) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis","volume":"15","author":"Vilas-Boas","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gut.49.2.303","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease","volume":"49","author":"Vlachogiannakos","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2010.03.013_bib38","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.2174\/092986706779026138","article-title":"Impact of inhibitors of the renin\u2013angiotensin\u2013aldosterone system on liver fibrosis and portal hypertension","volume":"13","author":"Tox","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2010.03.013_bib39","first-page":"44","article-title":"Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis","volume":"20","author":"Tsai","year":"1996","journal-title":"Proc Natl Sci Counc Repub China B"},{"key":"10.1016\/j.jhep.2010.03.013_bib40","first-page":"46","article-title":"Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites","volume":"86","author":"Okumura","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib41","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity","volume":"38","author":"Baik","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib42","first-page":"549","article-title":"Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension","volume":"39","author":"Svoboda","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/gast.2001.26295","article-title":"Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension","volume":"121","author":"Schepke","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1572-0241.2007.01759.x","article-title":"Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study","volume":"103","author":"Schepke","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000104819","article-title":"The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis","volume":"75","author":"Heim","year":"2007","journal-title":"Digestion"},{"key":"10.1016\/j.jhep.2010.03.013_bib46","first-page":"145","article-title":"Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension","volume":"21","author":"Sen","year":"2002","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib47","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.14.1908","article-title":"Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial","volume":"14","author":"De","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/jhep.2003.50032","article-title":"Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study","volume":"37","author":"Abecasis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1665-2681(19)32156-8","article-title":"A randomized study of losartan vs propranolol: effects on hepatic and systemic hemodynamics in cirrhotic patients","volume":"2","author":"Castano","year":"2003","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/A:1012993224326","article-title":"Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis","volume":"42","author":"Sugano","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2010.03.013_bib51","first-page":"893","article-title":"Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis","volume":"43","author":"Sugano","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0016-5085(99)70472-5","article-title":"Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution","volume":"117","author":"Garcia-Tsao","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib53","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0016-5085(90)91168-6","article-title":"Hemodynamic events in a prospective randomized trial of propranolol vs placebo in the prevention of the first variceal hemorrhage","volume":"99","author":"Groszmann","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/hep.1840360611","article-title":"\u201cA La Carte\u201d treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding","volume":"36","author":"Bureau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib55","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.03.013_bib56","doi-asserted-by":"crossref","first-page":"296A","DOI":"10.1016\/S0270-9139(03)80334-8","article-title":"Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis","volume":"38","author":"Aracil","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib57","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1872-034X.2009.00553.x","article-title":"New insights into the pathobiology of portal hypertension","volume":"39","author":"Guturu","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2010.03.013_bib58","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.510280405","article-title":"Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers","volume":"47","author":"Gracia-Sancho","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1572-0241.2000.01684.x","article-title":"Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites","volume":"95","author":"Alam","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.03.013_bib61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21309","article-title":"The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis","volume":"44","author":"Therapondos","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib62","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/jhep.2002.33637","article-title":"The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis","volume":"35","author":"Wong","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/gast.2001.25480","article-title":"Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis","volume":"121","author":"Jonsson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.03.013_bib64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(01)00146-5","article-title":"Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis","volume":"35","author":"Paizis","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.013_bib65","doi-asserted-by":"crossref","first-page":"39757","DOI":"10.1074\/jbc.M605621200","article-title":"Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis","volume":"281","author":"Zhou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.03.013_bib66","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000053185","article-title":"CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis","volume":"53","author":"Yang","year":"2000","journal-title":"Horm Res"},{"key":"10.1016\/j.jhep.2010.03.013_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/jhep.2001.28231","article-title":"Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats","volume":"34","author":"Yoshiji","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.013_bib68","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2010.03.013_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jhep.2010.03.013_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jhep.2010.03.013_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810003806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810003806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T23:10:19Z","timestamp":1591312219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827810003806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0168827810003806"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.03.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}